2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension

undefined; N Ruperto; DJ Lovell; R Cuttica; P Woo; G Espada; C Wouters; ED Silverman; Z Balogh; M Henrickson; J Davidson; I Foeldvari; L Imundo; G Simonini; J Oppermann; YK Shen; S Visvanathan; A Fasanmade; A Mendelsohn; A Martini; EH Giannini

Journal ArticleOPEN ACCESS

2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension

Ruperto N
Lovell D
et al.

Pediatric Rheumatology (2008) 6(S1)

DOI: 10.1186/1546-0096-6-s1-s3

N/ACitations

1Readers

Cite

CITATION STYLE

APA

Ruperto, N., Lovell, D., Cuttica, R., Woo, P., Espada, G., … Giannini, E. (2008). 2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension. Pediatric Rheumatology, 6(S1). https://doi.org/10.1186/1546-0096-6-s1-s3

2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension

Cite

Register to see more suggestions